RTP Mobile Logo
Cases from the Community: Clinical Investigators Provide Their Perspectives on the Use of Immune Checkpoint Inhibitors in the Management of Actual Patients with Genitourinary Cancers
Released April 2018

Proceedings from a CME symposium held at the 2018 Genitourinary Cancers Symposium. Featuring perspectives from Drs Charles G Drake, Peter H O’Donnell, Elizabeth R Plimack, Thomas Powles and David I Quinn. (Video Program)

CE Disclosures and Faculty Information

    This activity has been designed to meet the educational needs of medical oncologists and other allied healthcare professionals involved in the treatment of prostate cancer, urothelial bladder cancer and renal cell carcinoma (RCC).

    The past several years have seen an explosion in the emergence of new potential therapies that leverage the natural ability of the human body to attack and treat cancer. Known as immune-mediated therapies, or cancer immunotherapies, these promising treatments are taking center stage at medical conferences and generating excitement all over the world. Not surprisingly, with the many exciting advances rapidly occurring both within the field of genitourinary (GU) tumors and elsewhere, a number of vexing questions and clinical challenges are emerging simultaneously.

    These proceedings from a CME symposium during the Genitourinary Cancers Symposium explore the most significant therapeutic advances in the field of immunotherapy by using the perspectives of leading GU cancer experts on challenging cases and questions submitted by clinicians in the community to frame a relevant discussion of how this information has aided in the refinement of current routine clinical practice and ongoing research. This CME activity will help medical oncologists and other allied healthcare professionals find answers to the individualized questions and concerns that they frequently encounter and in turn provide high-quality cancer care.


    • Compare and contrast the mechanisms of action, efficacy and safety/toxicity of approved and investigational immunotherapies for the treatment of prostate cancer, RCC and bladder cancer to determine the current and/or potential utility of these agents in clinical practice.
    • Appraise the rationale for and clinical data with approved anti-PD-1 and anti-PD-L1 antibodies in patients with metastatic RCC and bladder cancer, and use this information to select patients for treatment with an immune checkpoint inhibitor.
    • Describe ongoing research to assist in the identification of biomarkers, tumor characteristics or other clinical features that are indicative of response to immune checkpoint inhibitors in patients with GU cancers.
    • Evaluate typical and atypical patterns of response to immune checkpoint inhibitors in an effort to identify patients who may or may not be benefiting from these agents.
    • Recognize immune-related adverse events and other common side effects associated with approved and developmental immune checkpoint inhibitors, and use this information to develop supportive management plans for patients with GU cancers undergoing treatment with these agents.
    • Consider available and emerging data with investigational anti-PD-1/PD-L1 antibodies alone or in combination with other systemic approaches currently in Phase II/III testing for select GU cancers, and, where applicable, refer eligible patients for trial participation or expanded access programs.

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    Research To Practice designates this enduring material for a maximum of 2.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 2.5 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.

    Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

    This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the Post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/GUCancers18/Immunotherapy/Video/CME.

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Charles G Drake, MD, PhD
    Professor of Medicine
    Co-Director, Cancer Immunotherapy Programs
    Columbia University Medical Center
    New York, New York

    Consulting Agreements: Agenus Inc, Dendreon Pharmaceuticals Inc, Genentech BioOncology, ImmuneXcite, Janssen Biotech Inc, Lilly, Merck, NexImmune, Pierre Fabre, Roche Laboratories Inc; Contracted Research: Aduro Biotech, Bristol-Myers Squibb Company, Janssen Biotech Inc; Patents: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Janssen Biotech Inc; Stockholder: Compugen, NexImmune, Potenza Therapeutics, Tizona Therapeutics Inc; Other: Bristol-Myers Squibb Company.

    Peter H O’Donnell, MD
    Assistant Professor, Department of Medicine
    Section of Hematology/Oncology
    Genitourinary Oncology Program
    The University of Chicago
    Chicago, Illinois

    Contracted Research: Acerta Pharma, AstraZeneca Pharmaceuticals LP/MedImmune, Boehringer Ingelheim Pharmaceuticals Inc, Genentech, A Member of the Roche Group, Janssen Biotech Inc, Merck, Seattle Genetics; Expert Testimony: Temple Health, Trinity Health; Honoraria: Algeta ASA, American Medical Forum, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Genentech, A Member of the Roche Group, Harrison Consulting, Inovio Pharmaceuticals Inc, Janssen Biotech Inc, Kantar Health, Merck, Novartis, PAREXEL International Corporation, Quintiles, Seattle Genetics, Xcenda; Stock: Allergan Inc; Travel: Merck.

    Elizabeth R Plimack, MD, MS
    Director, Genitourinary Clinical Research
    Associate Professor, Department of Hematology/Oncology
    Fox Chase Cancer Center, Temple Health
    Philadelphia, Pennsylvania

    Advisory Committee: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Exelixis Inc, Genentech BioOncology, Horizon Pharma, Inovio Pharmaceuticals Inc, Lilly, Novartis, Pfizer Inc, Roche Laboratories Inc; Contracted Research: Acceleron Pharma, Agensys Inc, a subsidiary of Astellas Pharma US, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Merck, Peloton Therapeutics Inc, Pfizer Inc.

    Thomas Powles, MBBS, MRCP, MD
    Professor of Urology Oncology
    Director of St Bartholomew’s Cancer Centre
    Queen Mary University of London
    London, United Kingdom

    Consulting Agreements: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Merck, Novartis, Pfizer Inc, Roche Laboratories Inc; Contracted Research: AstraZeneca Pharmaceuticals LP, Roche Laboratories Inc.

    David I Quinn, MBBS, PhD
    Medical Director, Norris Cancer Hospital and Clinics
    Head, GU Cancer Section
    Division of Cancer Medicine and Blood Diseases
    USC Norris Comprehensive Cancer Center
    Los Angeles, California

    Advisory Committee: Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Dendreon Pharmaceuticals Inc, Exelixis Inc, Genentech BioOncology, Janssen Biotech Inc, Merck, Pfizer Inc, Sanofi Genzyme; Consulting Agreements: Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Celgene Corporation, Dendreon Pharmaceuticals Inc, Exelixis Inc, Genentech BioOncology, Janssen Biotech Inc, Merck, Pfizer Inc, Sanofi Genzyme.

    MODERATOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Baxalta Inc, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, CTI BioPharma Corp, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite Pharma Inc, Lexicon Pharmaceuticals Inc, Lilly, Medivation Inc, a Pfizer Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, NanoString Technologies, Natera Inc, Novartis, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro Inc, Teva Oncology and Tokai Pharmaceuticals Inc.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Genentech BioOncology and Merck.

    Hardware/Software Requirements:
    A high-speed Internet connection
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 11 or later, Firefox 56 or later, Chrome 61 or later, Safari 11 or later, Opera 48 or later
    Adobe Flash Player 27 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Release date: April 2018
    Expiration date: April 2019

    After completing the Post-test, learners may download and review the answers here in order to identify further areas of study.

Acknowledge and close

Watch videos
(WIFI is recommended for best performance):


Current and Future Integration of Immune Checkpoint Inhibitors into the Management of Urothelial Bladder Cancer (UBC)

Existing and Emerging Role of Anti-PD-1/PD-L1 Antibodies in Renal Cell Carcinoma (RCC)

Clinical Trials of Immune Checkpoint Inhibition in Prostate Cancer (PC)

Patterns and Predictors of Response to Immune Checkpoint Inhibitors 

Incidence and Management of Toxicities Associated with Immune Checkpoint Inhibitors; Autoimmune Contraindications to Treatment

Select Publications